PharmaResources (Shanghai) Co. Ltd. A Asset Resilience Ratio
PharmaResources (Shanghai) Co. Ltd. A asset resilience ratio. PharmaResources (Shanghai) Co. Ltd. A (301230) has an Asset Resilience Ratio of 16.35% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of PharmaResources (Shanghai) Co. Ltd. A to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of PharmaResources (Shanghai) Co. Ltd. A (2021–2025)
Asset resilience ratio of PharmaResources (Shanghai) Co. Ltd. A from 2021 to 2025. This chart shows how PharmaResources (Shanghai) Co. Ltd. A's Asset Resilience Ratio has changed over time. Read PharmaResources (Shanghai) Co. Ltd. A (301230) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down PharmaResources (Shanghai) Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PharmaResources (Shanghai) Co. Ltd. A balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥215.15 Million | 16.35% |
| Total Liquid Assets | CN¥215.15 Million | 16.35% |
Asset Resilience Insights
- Good Liquidity Position: PharmaResources (Shanghai) Co. Ltd. A maintains a healthy 16.35% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
PharmaResources (Shanghai) Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare PharmaResources (Shanghai) Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
PharmaResources (Shanghai) Co. Ltd. A Asset Resilience Ratio by Year (2021–2025)
PharmaResources (Shanghai) Co. Ltd. A asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for PharmaResources (Shanghai) Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.95% | CN¥248.98 Million ≈ $36.43 Million |
CN¥1.31 Billion ≈ $192.29 Million |
-0.18pp |
| 2024-12-31 | 19.13% | CN¥251.77 Million ≈ $36.84 Million |
CN¥1.32 Billion ≈ $192.63 Million |
-3.79pp |
| 2023-12-31 | 22.92% | CN¥340.79 Million ≈ $49.87 Million |
CN¥1.49 Billion ≈ $217.62 Million |
+22.10pp |
| 2022-12-31 | 0.82% | CN¥10.65 Million ≈ $1.56 Million |
CN¥1.30 Billion ≈ $190.42 Million |
+0.75pp |
| 2021-12-31 | 0.07% | CN¥397.68K ≈ $58.19K |
CN¥557.81 Million ≈ $81.62 Million |
-- |
About PharmaResources (Shanghai) Co. Ltd. A
PharmaResources (Shanghai) Co., Ltd., together with its subsidiaries, operates as a one-stop integrated service provider for new drug research, development, and commercial manufacturing to pharmaceutical and biotechnology companies in China and internationally. The company offers contract research organization (CRO), contract manufacturing organization (CMO), contract development and manufacturin… Read more